Table 1.
Demographic and clinical characteristics of participants according to the presence of AF
| AF (204) | Non-AF (708) | P | |
|---|---|---|---|
| Age (years) | 68.78 ± 11.15 | 56.25 ± 10.31 | < 0.001 |
| Gender (male) | 132 (64.7) | 429 (60.6) | 0.287 |
| Smoke [(n%)] | 76 (37.3) | 305 (43.1) | 0.137 |
| HT [(n%)] | 149 (73.0) | 382 (54.0) | < 0.001 |
| DM [(n%)] | 64 (31.4) | 201 (28.4) | 0.408 |
| CHD [(n%)] | 121 (59.3) | 352 (49.7) | 0.016 |
| BMI (kg/m2) | 26.47 ± 2.95 | 25.89 ± 2.75 | 0.013 |
| SBP (mmHg) | 136.36 ± 20.15 | 130.84 ± 18.27 | < 0.001 |
| DBP (mmHg) | 80.09 ± 14.14 | 79.99 ± 12.76 | 0.934 |
| ALT (U/L) | 23.20 (17.25,29.18) | 24.35 (16.83,33.00) | 0.197 |
| AST (U/L) | 22.30 (18.50,27.60) | 22.70 (18.20,28.80) | 0.540 |
| Scr (mmol/L) | 71.00 (63.00,82.00) | 66.00 (56.00,75.00) | < 0.001 |
| TC (mmol/L) | 3.71 (3.10,4.50) | 4.43 (3.66,5.23) | < 0.001 |
| TG (mmol/L) | 1.81 (1.27,2.39) | 1.60 (1.24,2.09) | 0.008 |
| HDL-C (mmol/L) | 1.02 (0.90,1.19) | 1.10 (0.94,1.29) | < 0.001 |
| LDL-C (mmol/L) | 2.02 (1.49,2.57) | 2.38 (1.91,2.87) | < 0.001 |
| FBG (mmol/L) | 5.89 (5.24,7.65) | 5.50 (4.89,6.47) | < 0.001 |
| Anti-diabetic drugs[(n%)] | 55 (27.0) | 181 (25.6) | 0.688 |
| Lipid-lowering drugs[(n%)] | 73 (35.8) | 205 (29.1) | 0.062 |
| TyG | 9.12 ± 0.53 | 8.01 ± 0.44 | < 0.001 |
Values are expressed as mean ± standard deviation, no. (%), or median (interquartile range). P < 0.05 (two-sided) was defined as statistically significant
AF Atrial fibrillation, BMI body mass index, HT hypertension, DM diabetes mellitus, CHD coronary heart disease, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, Scr serum creatinine, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FPG fasting plasma glucose, TyG triglyceride-glucose index